Genes & Cancer

Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines

Dalil Hannani1, Estelle Leplus1, Karine Laulagnier1, Laurence Chaperot2 and Joël Plumas1,2

1 PDC*line Pharma, Grenoble, France

2 R&D Laboratory, Etablissement Français du Sang Auvergne Rhône-Alpes (EFS AURA), Grenoble, France


Joël Plumas, email:[email protected]

Keywords: cancer vaccine; neoantigens; plasmacytoid dendritic cells; immunotherapy

Received: August 25, 2022 Accepted: January 20, 2023 Published: January 30, 2023


In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. There is therefore a need to boost the frequency and function of patients’ cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. Here we discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells.

PII: 229